Isofol Medical AB (publ)

Stockholm Stock Exchange ISOFOL.ST

Isofol Medical AB (publ) Gross Profit for the year ending December 31, 2023: USD -3.40 M

Isofol Medical AB (publ) Gross Profit is USD -3.40 M for the year ending December 31, 2023, a 78.54% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Isofol Medical AB (publ) Gross Profit for the year ending December 31, 2022 was USD -15.83 M, a 29.41% change year over year.
Isofol Medical AB (publ) Gross Profit for the year ending December 31, 2021 was USD -22.42 M, a -13.89% change year over year.
Isofol Medical AB (publ) Gross Profit for the year ending December 31, 2020 was USD -19.68 M, a -11,805.26% change year over year.
Isofol Medical AB (publ) Gross Profit for the year ending December 31, 2019 was USD -165.35 K, a -836.14% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Stockholm Stock Exchange: ISOFOL.ST

Isofol Medical AB (publ)

CEO	Mr. Petter Segelman Lindqvist
IPO Date	April 4, 2017
Location	Sweden
Headquarters	Biotech Center
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.

Key trends

Past 5 years